# Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions

> **NCT01340625** · PHASE1 · COMPLETED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 36 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Norethindrone/Ethinyl Estradiol
- **DRUG:** Ovcon® 35 Fe

## Key facts

- **NCT ID:** NCT01340625
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2011-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01340625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01340625, "Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01340625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*